Video

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

R&D
JP Morgan interview with Jonah Comstock and Marianne De Backer

JP Morgan 2024 – Marianne De Backer

Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.

R&D
JP Morgan 2024 – Katherine Stueland and Jonah Comstock

JP Morgan 2024 – Katherine Stueland

Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.

R&D
Jonah Comstock and Frank Gleeson at JP Morgan

JP Morgan 2024 – Frank Gleeson

In this brief dispatch from JP Morgan, Editor in Chief Jonah Comstock grabs a few minutes with Frank Gleeson, CEO of Satellos Bioscience.